$LGND The board of Ligand Pharmaceuticals (LGND) raised the company's share buyback capacity to $350 million from the previous $200 million, Ligand said in a SEC filing released Monday. Ligand's share repurchase program will still expire as originally scheduled on Sept. 20, 2021. And according to the company, it has repurchased 745,811 common shares for a total of $105.6 million under the program as of Jan. 25.